WallStSmart
GTBP

GT Biopharma Inc

NASDAQ: GTBP · HEALTHCARE · BIOTECHNOLOGY

$0.31
+5.70% today

Updated 2026-06-02

Market cap
$15.74M
P/E ratio
P/S ratio
204.96x
EPS (TTM)
$-6.46
Dividend yield
52W range
$0 – $4
Volume
1.3M

GT Biopharma Inc (GTBP) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20062007200820092010201120122013201420152016201720182019202020212022202320242025
Operating cash flow$-671000.00$-270000.00$-169000.00$-937000.00$-1.53M$-963000.00$-987000.00$-442000.00$-1.75M$-4.66M$-1.93M$-5.43M$-10.68M$-3.66M$-7.26M$-15.61M$-15.22M$-8.85M$-12.90M$-12.91M
Capital expenditures$108000.00$97000.00$0.00$0.00$0.00$0.00$2000.00$0.00$6000.00$1000.00$4000.00$4000.00$36000.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Depreciation
Stock-based comp$1.84M$96000.00$146000.00$149000.00$307000.00$2.63M$3.76M$6.59M$130.12M$9.70M$5.31M$269000.00$33.93M$7.65M$2.20M$230000.00$432000.00
Free cash flow$-779000.00$-367000.00$-169000.00$-937000.00$-1.53M$-963000.00$-989000.00$-442000.00$-1.75M$-4.66M$-1.93M$-5.43M$-10.71M$-3.66M$-7.26M$-15.61M$-15.22M$-8.85M$-12.90M$-12.91M
Investing cash flow
Financing cash flow
Dividends paid$0.00$229000.00
Share repurchases
Debt repayment
Net change in cash$5.27M

Frequently asked questions

How much free cash flow does GTBP generate?

GTBP produced $-12.91M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is GTBP's balance sheet healthy?

GTBP holds $6.81M in cash and equivalents against — in long-term debt, on $5.79M of shareholder equity. That debt is best read against the cash flow the business throws off each year.